Statins: Hepatic Disease and Hepatotoxicity Risk

Raquel Cueto¹, Pedro Valdivielso², Mª Isabel Lucena*,¹,a, Carlota García-Arias², Raúl J. Andrade³,a and Pedro González-Santos²

¹Servicio de Farmacología Clínica, Hospital Clínico Universitario Virgen de la Victoria, Universidad de Málaga, Spain
²Unidad de Lípidos, Medicina Interna, Hospital Clínico Universitario Virgen de la Victoria, Universidad de Málaga, Spain
³Unidad de Hepatología, Servicio de Aparato Digestivo, Hospital Universitario Virgen de la Victoria, School of Medicine, Málaga, Spain
*aCentro de Investigación Biomédica en Red: Enfermedades Hepáticas y Digestivas (CIBERehd) – Málaga, Spain

Abstract: The hydroxy-methyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors generally have a good safety profile and are one of the most prescribed drugs in Europe. Nevertheless, differences in physicochemical and pharmacokinetic properties statins may translate into relevant differences in long term safety. In clinical trials, all lipid-lowering agents have been associated with mild asymptomatic elevation of aminotransferase enzymes. Studies that evaluate the risk of hepatotoxicity from statins in hyperlipidemic subjects with elevated baseline serum transaminases are lacking and furthermore, statins are considered contraindicated in patients with chronic liver disease. However, clinical and biochemical monitoring is routinely recommended or required, often to make up for the lack of information on the true risk of clinically significant liver toxicity of these agents in individuals both with and without underlying liver disease although there is no evidence that monitoring reduces the rate of hepatotoxicity. This article will review what is and what is not known about hepatic disease and hepatotoxicity risk due to the statins and offers recommendations for the safe and rational use of this group of drugs in the setting of specials situations.

Keywords: Hepatotoxicity, statins, drug interactions, chronic liver disease, fatty liver.

INTRODUCTION

Cardiovascular disease (CVD) is the principal cause of death in developed countries. It is estimated that almost 17 million people worldwide die every year due to this disease [1]. Tobacco consumption, hypertension, hyperlipidemia and diabetes, are the most important risk factors for CVD [2-4] and, in combination, exacerbate the associated morbimortality [5].

Statins are potent lipid-lowering drugs which reduce the concentrations of low density lipoprotein (LDL) cholesterol by inhibiting hydroxy-methyl glutaryl coenzyme A (HMG-CoA) reductase (the rate limiting enzyme in the intra-cellular biosynthesis of cholesterol) mainly in liver cells. Few drugs are prescribed as often as statins and this is a result of patient tolerance to these drugs and, as well, because of their efficacy [6-8]. In Spain in 2005 alone, 27.582.700 packets were prescribed (at a cost of around €727 million) and which represented a 10% increase over that sold in the year 2004. Atorvastatin is the most highly prescribed statin in Spain with a 15.46% increase in sales relative to 2003 [9].

Statins are not free from side effects despite being considered as safe drugs [10]. Although infrequent, hepatotoxicity and myopathy are two of the most common complications associated with this class of drugs [11, 12], especially when used at maximum doses, or when combined with other lipid lowering drugs such as fibrates, or combined with drugs that use the same enzymatic pathway as cytochrome P450 (CYP450) in its metabolic pathway, or in the elderly, or in subjects having considerable hepatic and/or renal dysfunction [13-16].

Since 2004, it has been possible to obtain simvastatin 10 mg over-the-counter in the United Kingdom and a potential increase in self-medication is forecast for the population which, in view of the aforementioned clinical profile which includes asymptomatic chronic hepatopathy and hyperlipidemia, the use of this class of drug requires an alteration in the safety code assigned to it.

The aim of this article is to review the available literature regarding the hepatotoxic potential of statins and their use despite common hepatic processes such as asymptomatic hypertransaminasemia and hepatitis C. We describe the current recommendations of their use designed to minimize the hepatotoxicity risk of these group of drugs.

HEPATOTOXICITY AND DRUGS

1. Definition

Hepatotoxicity is defined as the damage to the liver caused by drugs or chemicals. There are many substances capable of damaging the liver with several very different mechanisms and, as such, damage cannot be considered an
isolated pathology but more a compounding of factors involved in its development [17].

In 1989, consensus liver injury definition was an increase greater than twice the upper limit of the normal (ULN) range of the values of serum alanine aminotransferase (ALT) or of conjugated bilirubin, or even of a combined increase in the levels of aspartate aminotransferase (AST), alkaline phosphatase (AlkPhos), and total bilirubin (TB) provided that at least one of these parameters was >2 x ULN [18]. Since 2001, an ALT level of >3 x ULN and a total bilirubin level of >2 x ULN has been used in combination to define clinically-significant abnormal liver function, with confirmation required by additional clinical and laboratory data [19]. Hence, an isolated elevated level of transaminases does not necessarily indicate hepatotoxicity, and an increase of 3 x ULN may not be a sufficient biochemical criterion of hepatic lesion because of the considerable capacity of the liver to withstand damage [20, 21].

2. Clinical Presentation

The clinical presentation of hepatic toxicity is quite varied and encompasses asymptomatic or reversible alterations up to fulminant hepatic failure [22, 23]. Further, a toxic substance may sometimes present with different patterns of toxicity and, as such, it is not always possible to link a specific clinical pattern with a particular drug [24].

To incriminate a drug in the liver symptoms observed requires a high degree of suspicion on the part of the physician and includes a temporal relationship, awareness of the drug’s hepatotoxic potential, differential diagnosis and the exclusion of alternative causes of liver damage, and the ability to assess subtle data that favor a toxic etiology. Further, there are no specific analytical or clinical criteria for hepatotoxicity; exclusion of other possible etiologies being the only means of diagnosis currently available [25, 26].

Hepatotoxicity based on laboratory criteria may be classified as:

- Acute hepatocellular type: initial elevated ALT followed by an increase in the levels of bilirubin and AlkPhos; the latter, however, being quite modest. The ALT/AlkPhos ratio (R) expressed as a function of the ULN values would be R ≥5 [18] and describes patients with a presentation similar to that of acute viral hepatitis, together with general discomfort, anorexia and nausea. Prognosis would vary substantially and be related to the extent of liver damage [27].

- Acute cholestatic injury: the initial rises are in the AlkPhos values, which are more prominent and precocious than ALT or AST and with an R value ≤2 [18]. The condition can be classified into two types:

  - Pure, soft or canalicular: clinically features include jaundice and pruritus. The condition is characterized by an increase in conjugated bilirubin, AlkPhos and γ-glutamyl transpeptidase (γ-GT) with little or no impairment in serum transaminases. Liver histology shows hepatocyte cholestasis and dilated biliary canaliculi with bile-plugs [28]. It has a good prognosis following laboratory and clinical normalization.

  - Mixed hepatic injury: is used to describe the clinical and biological picture which is intermediate between the hepatocellular and cholestatic types, with features of either type predominating. Laboratory measurements show an elevated ALT >2 x ULN with an increment of AlkPhos and R >2 but R<5 [18]. Hypersensitivity features are often present, as well as a granulomatous reaction in the liver biopsy specimen [29].

- Chronic hepatocellular injury: information is scarce on this condition and what information is available is generally derived from isolated cases [30]. Recently, in a chronic cases study, the most frequent lesion observed was mixed/cholestatic damage and the drugs most often associated with the condition were hypolipemic agents and antihypertensive medications [31, 32]. The condition is defined by persistent elevation of the aminotransferases for >3 months in cases of hepatocellular damage and >6 months in cholestatic/mixed case. The toxicity is, presumably, a consequence of continuing the particular treatment, or may be related to other specific drugs such as diclofenac or nitrofurantoin [33].

3. Treatment

In the majority of cases there is no effective treatment for the restitution of hepatic function following damage induced by a drug or its active metabolites. In the presence of either clinical or laboratory suspicion of hepatotoxicity, the first course of action is to discontinue the probable culprit substance or substances. It is important to follow-up these patients with regular monitoring of liver tests and with specialist collaboration. Clinical improvement occurs, in the majority of cases, when the culprit drug is discontinued, although in some cases the hepatotoxic reaction may well worsen weeks after the drug withdrawal, as is the case with amoxicillin-clavulanic acid [34].

Hepatotoxicity in Trials with Statins

Abnormalities in liver function tests have been investigated in a wide range of randomized clinical trials, when comparing different doses of statins with either placebo or another comparator (Table 1). In a meta-analysis of randomized clinical trials (RCTs) of fluvastatin, pravastatin, lovastatin and simvastatin at low or moderate doses (<40 mg oral), the prevalence of elevated transaminases >3 x ULN was similar in the active treatment groups compared to the placebo groups, but only slightly higher in two studies of fluvastatin versus placebo (1.13% vs 0.39%, p=0.04) [35]. However, atorvastatin despite being the most-prescribed statin had not been included in this meta-analysis. When analyzing large-scale RCTs where high-dose atorvastatin was used (80 mg oral), the prevalence of asymptomatic elevations of transaminases >3 x ULN was slightly higher (~3%) compared to placebo, or with another statin at moderate dose (Table 2) [36-39]. In comparing the effects of 10mg versus 80 mg daily atorvastatin, it appears that the frequency
of an abnormal transaminase value is 0.6% for the 10 mg dose, increasing up to 3.3% for the 80 mg dose [40, 41]. This safety profile is maintained even in individuals >65 years of age [42]. Hence, in summary, the risk of hypertransaminasemia or acute hepatitis associated with these drugs as seen in the clinical trials, is no higher than the risk in the placebo group when using the low or moderate doses.

Table 1. Percentages of Transaminase Increases in Patients Treated with Placebo and Different Dose of Statins (Denus 2004) [35]

<table>
<thead>
<tr>
<th>Statin</th>
<th>Placebo</th>
<th>STATIN Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>10 mg</td>
</tr>
<tr>
<td>Lovastatin</td>
<td>0.1%</td>
<td>-</td>
</tr>
<tr>
<td>Simvastatin</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Pravastatin</td>
<td>1.3%</td>
<td>-</td>
</tr>
<tr>
<td>Fluvastatin</td>
<td>0.3%</td>
<td>-</td>
</tr>
<tr>
<td>Atorvastatin</td>
<td>-</td>
<td>0.2%</td>
</tr>
</tbody>
</table>

An Alanine transaminase increases superior to three times the upper limit of normality.

Nonetheless, in large-scale RCTs with statins, an exclusion criterion is the presence of hypertransaminasemia or active liver disease and, therefore, the hepatotoxic risks that these drugs can provoke in standard clinical practice are not assessed. A Medline search (dated October 5th 2007) using acute hepatitis and statins as MeSH terms revealed only 37 original entries reporting cases of acute hepatitis caused by these drugs. Further, in a national registry for drug-related hepatic reactions in which 461 episodes were recorded, only 11 (2.3%) were attributable to statins [31]. These data confirm the low incidence of severe adverse hepatic reactions provoked by the use of HMG-CoA reductase inhibitors.

STATINS AND COMMON CLINICAL SITUATIONS

1. Asymptomatic Hypertransaminasemia

In standard clinical practice it is not infrequent to prescribe statins for patients with asymptomatic hypertransaminasemia. Once viral infection has been excluded, the majority of these subjects are described as having “fatty liver”[43], an entity that has become the most frequent hepatic lesion in patients suffering from NAFLD, followed by chronic liver disease [48]. Also, NAFLD is associated with the Metabolic Syndrome (Table 3) [49], an entity which, based on the guidelines of the National Cholesterol Education Program-Adult treatment Panel III (NCEP-ATP III), increases the predisposition to cardiovascular disease [50, 51]. Indeed, approximately 80% of patients with non-alcoholic steatohepatitis, as confirmed by biopsy, fulfill the criteria for the diagnosis of Metabolic Syndrome [52].

Statins being the drugs-of-choice in the treatment of hypercholesterolemia and, as well, in the prevention of cardiovascular disease, it would be of interest to evaluate whether the presence of hypertransaminasemia could lead to a poorer prognosis if the patients receive treatment with statins. In this respect the publications by Chalasani et al. [53] and by Vuppalanchi et al. [54] are of considerable interest. Chalasani et al. retrospectively evaluated the hepatotoxicity risk in subjects treated for at least 6 months with atorvastatin, simvastatin or fluvastatin. Drawn from the pharmacological registry of an insurance company, the subjects were segregated into two groups: one group with elevated transaminases before treatment (cohort I; n = 342) and another group with normal levels of transaminases (cohort II; n = 1435). Both groups were compared with a third group with hypertransaminasemia but not receiving lipid-lowering drugs (cohort III, n=2245). Alcoholic or viral etiology was excluded in all of the three groups. The authors’ criteria for “low-moderate elevation” was an increase of ALT and/or AST >3 x baseline values. By contrast, an increase of ALT and/or AST >10 x baseline value or total bilirubin values >3 mg/dL, were considered as “severe reaction”. Incidence of low-moderate elevations was 4.7%, 1.9% and 6.4%, respectively, in the three cohorts (p<0.05) while incidence of severe reactions was 0.6%, 0.2% and 0.4% (p>0.2). The authors concluded that patients who already have moderate hypertransaminasemia before starting treatment are not at higher risk of statin-induced hepatotoxicity.

Another more recent study by Vuppalanchi et al. [54] analyzed the effects of 1 year treatment with lovastatin. The three cohorts evaluated followed the same criteria used by Chalasani et al. The number of participants in each group was 135 in cohort I, 620 in cohort II and 2644 patients in cohort III. The study had an additional hepatic lesion criterion introduced. Termed the Hy’s rule, the criterion is based on the presence of ALT and/or AST >3 x ULN, plus bilirui-
Table 3. Main Analytical Characteristics of the Metabolic Syndrome

<table>
<thead>
<tr>
<th>Lipoproteins</th>
<th>Glycemia</th>
<th>Blood Pressure</th>
<th>Waist Circumference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Triglycerides ≥ 150 mg/dL</td>
<td>glucose ≥110 mg/dL.</td>
<td>≥ 130/85 mmHg</td>
<td>&gt;102 cm (Males)</td>
</tr>
<tr>
<td>High density lipoprotein:</td>
<td></td>
<td></td>
<td>&gt;88 cm (Females)</td>
</tr>
<tr>
<td>&lt; 40 mg/dL (Males)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 50 mg/dL (Females)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

bin > 2 x ULN in the course of the observation period, and which is considered as clinically-evident hepatitis, with a 10% mortality [55]. Results were super-imposable on those obtained in the study by Chalasani et al. Of note is that none of the patients in cohorts I and II matched the Hy’s criteria, while its prevalence was 3% in cohort III. It is clear that a substantial proportion of patients (4.6% from cohort I and 4.5% from cohort II of the initial study) showed ALT and/or AST > 3 x ULN. Since this event is considered a benign hypertransaminasemia it has become usual practice to reduce, or discontinue, treatment with statins and which, in the short term, results in a reduction in therapeutic efficiency.

Despite that the majority of patients from the two studies mentioned above suffering from NAFLD and, as well, that a non-controlled study suggested an analytic benefit (reductions in aminotrasferase, AlkPhos, and γ-GT) in NAFLD patients treated with atorvastatin 10 mg [56], there have not been any randomized clinical trials that support the conclusion that the use of statins in this clinical context would provide benefit with respect to the resolution of histological lesions and protection against the progression of the disease towards fibrosis and cirrhosis.

2. Patients with Chronic Hepatitis C

Hepatitis C virus (HCV) infection is the most frequent cause of long-term hepatic lesion. Nearly 170 million people world-wide are infected with the virus, most being asymptomatic carriers with minimal change in the levels of the hepatic enzymes [57, 58]. Because of its high incidence, it is not unusual to find patients with chronic HCV and hyperlipidemia being treated with lipid lowering drugs, mainly statins.

HCV patients have been excluded from clinical trials with statins because of the perceived increased risk of hepatic toxicity. However, two recent studies have shown an absence of significant liver enzyme elevation in infected versus control groups. In an early review [59] of 219 patients with chronic HCV, 17 were receiving statin treatment for at least 3 months. Only 5 patients had any liver enzyme elevation while on a statin, and the highest increase was 1.5 x ULN. A subsequent study [60] followed 3 cohorts of patients for 12 months and compared the values of the transaminases in follow-up with those recorded at baseline. Cohort I was composed of 166 patients with hyperlipidemia and HCV positive and had statins administered; Cohort II was composed of 332 patients with HCV-antibody positive and were not receiving statins treatment; Cohort III was composed of 332 patients with negative HCV antibodies and hyperlipidemia and receiving statins. When cohort I and II were compared, a higher frequency of moderate elevations of aminotrasferases (23% vs 13%; p<0.05) was observed as well as, paradoxically, a lower frequency of acute elevations (1.2% vs 6.6%; p<0.05) in cohort I compared to cohort II. When comparing cohorts I and III, the moderate increase appeared very similar for both groups (22.9% vs 16.3%; p=0.094) as did the severe increase (1.2% vs 1%; p=0.874) and when the hepatotoxic treatment was withdrawn (21.6% vs 9.2%; p=0.147). The conclusion was that lipid lowering therapy with statins in patients with chronic HCV is not associated with a significant increase in hepatotoxicity risk [59]. However, additional studies would be necessary to corroborate these findings, particularly in cases of severe infection.

The standard treatment for hepatitis C patients is based on the combination of pegylated interferon and ribavirin, although the effectiveness is limited to approximately 55% of patients [61]. Lovastatin appears to inhibit HCV RNA replication by inhibiting the geranylgeranylation of cellular proteins rather than the inhibition of cholesterol synthesis [62]. A recent publication of Ikeda et al. reported that lovastatin, fluvastatin, atorvastatin and simvastatin, but not pravastatin, inhibit HCV RNA replication in vitro cell culture [57]. Further, all statins, except pravastatin, markedly enhanced the anti-HCV effect of IFN-α [57]. Differences observed between pravastatin and other statins could be related to pravastatin’s absence of metabolic processes via cytochrome P450 (Table 4) [63, 64].

3. Patients with Primary Biliary Cirrhosis

Primary biliary cirrhosis is a chronic progressive cholestatic disorder characterized by a marked increase of cholesterol, mainly due to Lp X particles, that may elevate the risk of coronary heart disease [65]. Two small trials evaluated the role of simvastatin [66] and atorvastatin [67], indicating that both drugs were able to reduce total cholesterol as expected; however, no clear improvement in cholestatic parameters were observe It is worth pointing out that these trials included only 21 patients followed-up for just 6 and 8 weeks. In summary, additional larger scale, prospective studies are required to determine the efficacy of statins in this population.

CONCLUSIONS AND RECOMMENDATIONS

Statins are the first-line therapy for patients with dyslipidemia involving elevated LDL, and for the prevention of cardiovascular disease. Despite being among the most widely prescribed drugs on the market, there is a dearth of reported cases of hepatotoxicity. The frequency of elevated aminotrasferase is <1% for low-to-moderated doses (≤40 mg) and reaches 3% for high doses (80 mg). Therefore, the risk of suffering from liver failure as a consequence of this class of drugs, is low i.e. approximately about 1 per million, according to notification to regulatory authorities [12].
The evidence that patients with baseline hypertransaminasemia are not at a higher risk of hepatotoxicity when receiving statins than the general population prompts the consideration these drugs are beneficial in the treatment vascular risk associated to NAFLD. None of the current studies would formally contraindicate the prescription of statins for patients with hepatitis C, although we should keep in mind the low number of participant in such studies. Further, the use of this class of drugs in combination with interferon to improve the conventional treatment efficiency is currently being investigated.

As already stated, there is no evidence that statin therapy should be altered or discontinued solely on the basis of elevated aminotransferase levels in an asymptomatic patient. Should more objective evidence of hepatic dysfunction be identified, such as hepato-megaly, clinical evidence of jaundice, elevated direct bilirubin, or increased prothrombin time, discontinuation of statin therapy ought to be considered [68]. In the absence of biliary obstruction, the plasma concentration of bilirubin is a more reliable prognostic factor of liver injury, in the drug toxicity setting. If the direct fraction of bilirubin is found to be increased together with elevated aminotransferases, it is reasonable to assume that there is ongoing liver injury and further appropriate laboratory and clinical evaluation should be undertaken to ascertain the etiology.

Once a patient recovers from a hepatotoxic episode induced by statins, it is worthy to re-evaluate the need for cholesterol-lowering drugs. If this is the case, in addition to low-cholesterol and low-saturated fat diet, the alternatives would be resins or ezetimibe. In the subset of patients with a very high vascular risk (i.e. diabetics with coronary heart disease already present), then it would be necessary to switch from resins or ezetimibe. In the subset of patients with a very high vascular risk (i.e. diabetics with coronary heart disease already present), then it would be necessary to switch fromLovastatin or pravastatin) or vice-versa. Careful evaluation of the risk/benefit ratio and close monitoring should be followed.

ACKNOWLEDGEMENT
CIBERehd is funded by Instituto de Salud Carlos III.

REFERENCES

Table 4. Pharmacokinetic Parameters of Statins

<table>
<thead>
<tr>
<th></th>
<th>Lovastatin</th>
<th>Simvastatin</th>
<th>Pravastatin</th>
<th>Fluvastatin</th>
<th>Atorvastatin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lipophilic</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Protein binding</td>
<td>&gt;95%</td>
<td>95-98%</td>
<td>50%</td>
<td>&gt;98%</td>
<td>98%</td>
</tr>
<tr>
<td>CYP450</td>
<td>CYP3A4</td>
<td>CYP3A4</td>
<td>No</td>
<td>CYP2C9</td>
<td>CYP3A4</td>
</tr>
<tr>
<td>Half life</td>
<td>3h</td>
<td>2h</td>
<td>1.8h</td>
<td>1.2h</td>
<td>1.4h</td>
</tr>
<tr>
<td>Active metabolites</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Bd</td>
<td>5%</td>
<td>5%</td>
<td>18%</td>
<td>19-30%</td>
<td>12%</td>
</tr>
<tr>
<td>Urinary Excretion</td>
<td>10%</td>
<td>13%</td>
<td>20%</td>
<td>6%</td>
<td>2%</td>
</tr>
<tr>
<td>Tmax</td>
<td>2-4 hour</td>
<td>1.3-2.4 hour</td>
<td>0.9-3.6 hour</td>
<td>0.5-1 hour</td>
<td>2-3 hour</td>
</tr>
</tbody>
</table>

Bd: Bio-availability; Tmax: time to peak concentration.
Statins: Hepatic Disease and Hepatotoxicity Risk

The Open Gastroenterology Journal, 2008, Volume 2


